Efficacy and Tolerability of Switching to Ziprasidone in Italian Patients with Acute Exacerbation of Schizophrenia: An Open-Label Trial

Abstract

Introduction:

The long-term maintenance of a stable condition is an important aim of schizophrenia therapy, which frequently requires the switch between 2 antipsychotic agents. This 8-week multicenter study, conducted in Italy, evaluates the switch from a previous antipsychotic to ziprasidone.

Methods:

Adult acute schizophrenic patients requiring a change in antipsychotic for lack of efficacy or tolerability issues took ziprasidone 20 − 80 mg/bid. Dosages could be adjusted during the study. The primary efficacy outcomes were the differences in positive and negative syndrome scale (PANSS) and clinical global impression severity (CGI-S) scores from baseline to study end. Other efficacy variables were clinical global impression improvement, global assessment of functioning, patient preference scale and drug attitude inventory.

Results:

189 patients were evaluated; the mean (±SD) ziprasidone dose was 95.9±34.5 mg/day. PANSS and CGI-S scores significantly decreased throughout the study. All secondary outcomes significantly improved at the end of the study vs. baseline values. Ziprasidone was well tolerated; 13 patients reported a QTc prolongation (mild in 12 patients).

Discussion:

Notwithstanding the limitations of any non-comparative study, these results suggest that ziprasidone may be an effective and well-tolerated option in acute schizophrenia patients who discontinued a previous antipsychotic agent.

Key words

acute exacerbation - antipsychotic agents - schizophrenia - switch - ziprasidone

• References

• 1 Vohora D. Atypical antipsychotic drugs: current issues of safety and efficacy in the management of schizophrenia. Curr Opin Investig Drugs 2007; 8: 531-538
• 2 Weiden PJ. Switching in the era of atypical antipsychotics. An updated review. Postgrad Med 2006; Spec No: 27-44
• 3 Motlová L, Spaniel F, Höschl C et al. Are there any differences in the efficacy among second generation antipsychotics in the treatment of schizophrenia and related disorders?. Ann Clin Psychiatry 2007; 19: 133-143
• 4 Komossa K, Rummel-Kluge C, Hunger H et al. Ziprasidone versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev 2009; 4 CD006627
• 5 Swainston Harrison T, Scott LJ. Ziprasidone: a review of its use in schizophrenia and schizoaffective disorder. CNS Drugs 2006; 20: 1027-1052
• 6 Haddad PM, Sharma SG. Adverse effects of atypical antipsychotics: differential risk and clinical implications. CNS Drugs 2007; 21: 911-936
• 7 Greenberg WM, Citrome L. Ziprasidone for schizophrenia and bipolar disorder: a review of the clinical trials. CNS Drug Rev 2007; 2: 137-177
• 8 Citrome L. Using oral ziprasidone effectively: the food effect and dose-response. Adv Ther 2009; 26: 739-748
• 9 Pfizer Inc Geodon^® (ziprasidone HCl) capsules; Available from URL: http://www.pfizer.com/files/products/uspi_geodon.pdf. Last accessed: 27^th September 2010
• 10 International Approvals. Zeldox, Alfimeprase, Bronchitol. Available from URL: http://www.medscape.com/viewarticle/517021 Last accessed: 27^th September 2010
• 11 Simpson GM. Benefits of ziprasidone in stable outpatient schizophrenics switched from conventional antipsychotics, olanzapine or risperidone. Int J Neuropsychopharm 2000; 3 (Suppl. 01) S157-S158
• 12 Harvey PD, Meltzer HY, Romano S. Improvement in cognition following a switch to open-label ziprasidone from olanzapine, risperidone and conventional antipsychotics. Eur Neuropsychopharm 2000; 10 (Suppl. 03) S288
• 13 Daniel DG. Improvement in indices of health status following a switch to ziprasidone from conventional and novel antipsychotics. Int J Neuropsychopharm 2000; 3 (Suppl. 01) S159
• 14 Weiden PJ, Daniel DG, Simpson G et al. Improvement in indices of health status in outpatients with schizophrenia switched to ziprasidone. J Clin Psychopharmacol 2003; 23: 595-600
• 15 Weiden PJ, Simpson GM, Potkin SG et al. Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophrenia. J Clin Psychiatry 2003; 64: 580-588
• 16 Stroup TS, Lieberman JA, McEvoy JP et al. CATIE investigators . Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry 2006; 163: 611-622
• 17 Rossi A, Cañas F, Fagiolini A et al. Switching among antipsychotics in everyday clinical practice: focus on ziprasidone. Postgrad Med 2011; 123: 135-159
• 18 Dunn J, Simpson GM, Fayek M et al. Ziprasidone: long-term post-switch efficacy in schizophrenia. Eur Neuropsychopharmacol 2004; 14 (Suppl. 03) S269-S270
• 19 Harvey PD, Meltzer H, Simpson GM et al. Improvement in cognitive function following a switch to ziprasidone from conventional antipsychotics, olanzapine, or risperidone in out patients with schizophrenia. Schizophr Res 2004; 66: 101-113
• 20 Lieberman JA, Stroup TS, McEvoy JP et al. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353: 1209-1223
• 21 Kessing LV, Thomsen AF, Mogensen UB et al. Treatment with antipsychotics and the risk of diabetes in clinical practice. Br J Psychiatry 2010; 197: 266-271